We are monitoring the impact of COVID-19 on North America ADHD Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 265
Share on
Share on

North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report – Segmented By Treatment, Medication, Psychotherapy, Education Or Training & By Country (US, Canada & Rest of North America) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 265
Pages: 145

North America ADHD Therapeutics Market Size (2021 to 2026)

The size of the North American Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to grow USD 5.52 billion by 2026 from USD 3.90 billion in 2021, growing at a CAGR of 7.20% during the forecast period 2021 to 2026.

ADHD is becoming more common due to the lack of therapy, which is driving the market for attention deficit hyperactivity disorder therapies. In addition, the ADHD treatments market is being driven by the harsh effect of unstable lifestyles and preservatives in children's meals, increasing the occurrence of ADHD in the 4–7 years age group. 

Rising awareness of the syndrome among physicians and patients and a lack of routine diagnostic tests are expected to drive the North American ADHD market growth during the forecast period. In addition, other factors such as the rising medical developments, a growing number of neuroscience research projects, and increased public awareness about mental illness are expected to boost the market’s growth rate. 

On the other hand, the expansion of biotechnology and pharmaceutical companies’ focus on creating innovative therapies for ADHD is driving the market growth in the North American region. Furthermore, the adoption of cutting-edge technology in health care facilities, increasing healthcare spending, and rising disposable income are expected to propel the ADHD therapeutics market ahead in this region.  In addition, the medical sector's focus on improving infrastructure, the rising prevalence of various health diseases, and the expanding number of elderly populations are expected to showcase a significant positive impact on the market’s growth rate during the forecast period.

However, strict government laws governing the approval of medicines associated with neurosciences and the acceptable cost of ADHD medication are limiting the market expansion in North America. Another issue that limits growth is the use of ADHD medications, which are rarely used.

This research report on the North America ADHD therapeutics market has been segmented and sub-segmented into the following categories:

By Medication:

  • Stimulants
  • Non-Stimulants

By Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioural Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

By Education or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

By Country:

  • the United States
  • Canada
  • Rest of North America

Geographically, the North American regional market held the largest share of the worldwide ADHD therapeutics market in 2020, accounting for around 36% due to a well-developed economy, early adoption of sophisticated technology, and high per capita healthcare costs. In addition, the presence of established companies in the region and due to the introduction of products by regional players during the forecast period, for example, Adlon Therapeutics L.P., a Purdue Pharma L.P. company, gained FDA clearance in March 2019 for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder in patients aged six years and older.

The U.S. ADHD therapeutics market dominated the North American market, and it is anticipated to register a predominant share during the forecast period. The growing number of patients with attention deficit hyperactivity disorder (ADHD) and high healthcare costs drive the market growth. Also, the availability of advanced healthcare infrastructure, increasing healthcare spending, and favorable reimbursement policies fuel market growth. 

KEY MARKET PLAYERS:

A few of the prominent companies operating in the North America attention deficit hyperactivity disorder (ADHD) therapeutics market are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Introduction                                               

                5.2 Treatment By Medication                                    

                                5.2.1 Introduction                           

                                5.2.2 Stimulants                               

                                                5.2.2.1 Introduction       

                                                5.2.2.2 Amphetamines 

                                                5.2.2.3 Methylphenidate             

                                                5.2.2.4 Dextroamphetamine      

                                                5.2.2.5 Dexmethylphenidate     

                                5.2.3 Non-Stimulants                     

                                                5.2.3.1 Introduction       

                                                5.2.3.2 Atomoxetine      

                                                5.2.3.3 Bupropion           

                                                5.2.3.4 Guanfacine         

                5.3 Treatment By Psychotherapy                                             

                                5.3.1 Introduction                           

                                5.3.2 Behavior Therapy                 

                                5.3.3 Cognitive Behavioral Therapy                         

                                5.3.4 Interpersonal Psychotherapy                         

                                5.3.5 Family Therapy                      

                5.4 Treatment By Education or Training                                 

                                5.3.1 Introduction                           

                                5.3.2 Parent Management Training                         

                                5.3.3 Social Skills Training                             

                                5.3.4 School-Based Interventions                            

  1. Geographical Analysis

                                6.1 Introduction                               

                                6.2 United States                            

                                6.3 Canada                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Shire plc (Ireland)                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Neos Therapeutics, Inc. (U.S.)                                            

                8.3 Eli Lilly and Company (U.S.)                                  

                8.4 Pfizer Inc. (U.S.)                                       

                8.5 Alcobra Ltd. (Israel)                                 

                8.6 Supernus Pharmaceuticals, Inc. (U.S.)                                            

                8.7 Noven Pharmaceuticals, Inc. (U.S.)                                  

                8.8 Novartis AG (Switzerland)                                    

                8.9 Johnson & Johnson (U.S.)                                    

                8.10 Curemark, LLC., (U.S.)                                         

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  3. North America Stimulants Market By Region, From 2021 to 2026 (USD Billion)
  4. North America Non-Stimulants Market By Region, From 2021 to 2026 (USD Billion)
  5. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  6. North America Behavior Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  7. North America Cognitive Behavioral Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  8. North America Interpersonal Psychotherapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  9. North America Family Therapy ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  10. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  11. North America Parent Management Training ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  12. North America Social Skills Training ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  13. North America School-based Interventions ADHD Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  14. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  15. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  16. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  17. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2021 to 2026 (USD Billion)
  18. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2021 to 2026 (USD Billion)
  19. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2021 to 2026 (USD Billion)
  20. North America Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  21. North America Amphetamines Market By Region, From 2021 to 2026 (USD Billion)
  22. North America Methylphenidate Market By Region, From 2021 to 2026 (USD Billion)
  23. North America Dextroamphetamine Market By Region, From 2021 to 2026 (USD Billion)
  24. North America Dexmethylphenidate Market By Region, From 2021 to 2026 (USD Billion)
  25. United States Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  26. Canada Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  27. North America Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  28. North America Atomoxetine Market By Region, From 2021 to 2026 (USD Billion)
  29. North America Bupropion Market By Region, From 2021 to 2026 (USD Billion)
  30. North America Guanfacine Market By Region, From 2021 to 2026 (USD Billion)
  31. United States Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)
  32. Canada Non-Stimulants ADHD Therapeutics Market By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample